October 1, 2002The Medical Journal of Australia
Cholesterol‐lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: is it cost‐effective?
Why the study?
Does pravastatin 40 mg daily improve cost-effectiveness in patients with established ischaemic heart disease and average cholesterol levels?
Population
9014 patients aged 35-75 years with a history of unstable angina or previous myocardial infarction and…
Comparison
Pravastatin 40 mg daily vs Matching placebo
Design
RCT, randomised, double-blind
Follow-up
mean 6 years
Authors
Discussion
Loading...
Member takes
Implication
Supports pravastatin as cost-effective secondary prevention in IHD; reinforces use in patients with average cholesterol levels.
Structured PICO
Does pravastatin 40 mg daily improve cost-effectiveness in patients with established ischaemic heart disease and average cholesterol levels?
P
Population
9014 patients aged 35-75 years with a history of unstable angina or previous myocardial infarction and average baseline cholesterol levels
I
Intervention
Pravastatin 40 mg daily
C
Comparator
Matching placebo
O
Outcome
Cost per death averted, cost per life-year gained, and cost per quality-adjusted life-year gained
Pravastatin therapy is cost-effective for secondary prevention in patients with established ischemic heart disease and average cholesterol levels.
Cite This Study
Glasziou et al. (2002) studied this question.